Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE3
Impact of Endogenous E2 on SSI and GH Rebound
- Status
- COMPLETED
- Phase
- PHASE1
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Status
- TERMINATED
- Phase
- PHASE2
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- Status
- COMPLETED
- Phase
- PHASE2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3023414 in Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
- Status
- TERMINATED
- Phase
- PHASE3
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
- Status
- COMPLETED
- Phase
- PHASE3
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2